[HTML][HTML] Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

DK Nambiar, D Mishra, RP Singh - Oncology research, 2023 - ncbi.nlm.nih.gov
Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …

Quiescent cancer cells—a potential therapeutic target to overcome tumor resistance and relapse

E Lindell, L Zhong, X Zhang - International Journal of Molecular Sciences, 2023 - mdpi.com
Quiescent cancer cells (QCCs) are nonproliferating cells arrested in the G0 phase,
characterized by ki67low and p27high. QCCs avoid most chemotherapies, and some …

Discovery of KB-0742, a potent, selective, orally bioavailable small molecule inhibitor of CDK9 for MYC-dependent cancers

DB Freeman, TD Hopkins, PJ Mikochik… - Journal of Medicinal …, 2023 - ACS Publications
Transcriptional deregulation is a hallmark of many cancers and is exemplified by genomic
amplifications of the MYC family of oncogenes, which occur in at least 20% of all solid …

Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review

F Peytam, Z Emamgholipour, A Mousavi, M Moradi… - Bioorganic …, 2023 - Elsevier
Considering the fundamental role of protein kinases in the mechanism of protein
phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has …

CircNCOR1 regulates breast cancer radiotherapy efficacy by regulating CDK2 via hsa-miR-638 binding

ZY He, RG Zhuo, SP Yang, P Zhou, JY Xu, J Zhou… - Cellular …, 2023 - Elsevier
Background Despite aggressive local and regional therapy, triple-negative breast cancer
(TNBC) is characterized by an increased risk of locoregional recurrence. RNA-sequencing …

Mechanism of CDK4/6 inhibitor resistance in hormone receptor-positive breast cancer and alternative treatment strategies

CM Chang, HYP Lam - Anticancer Research, 2023 - ar.iiarjournals.org
Breast cancer (BC) is a common malignancy in women, with hormone receptor (HR)-positive
subtype responsible for approximately 70% of cases. Currently, patients with metastatic HR …

A Systematic Review of Stem Cell Differentiation into Keratinocytes for Regenerative Applications

R Hazrati, S Davaran, P Keyhanvar, S Soltani… - Stem Cell Reviews and …, 2024 - Springer
To improve wound healing or treatment of other skin diseases, and provide model cells for
skin biology studies, in vitro differentiation of stem cells into keratinocyte-like cells (KLCs) is …

Design, synthesis, antineoplastic activity of new pyrazolo [3, 4-d] pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME …

MTM Nemr, A Elshewy, ML Ibrahim, AM El Kerdawy… - Bioorganic …, 2024 - Elsevier
In the current study, novel pyrazolo [3, 4-d] pyrimidine derivatives 5a–h were designed and
synthesized as targeted anti-cancer agents through dual CDK2/GSK-3β inhibition. The …

Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions

R Gerosa, R De Sanctis, F Jacobs, C Benvenuti… - Critical Reviews in …, 2024 - Elsevier
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main
resistance mechanism to CDK4/6 inhibition in hormone-positive (HR+) breast cancer …

[HTML][HTML] Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519

K Karaś, I Karwaciak, K Chałaśkiewicz… - Biomedicine & …, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancerous tumors and one of
the leading causes of death among cancer-related disorders. Chemotherapy is ineffective in …